Sign In
Buy SRPT
$16.24
-0.0100 (-0.0615%)
At Close: Jun 03, 2026
Sarepta Therapeutics Provides Statement on ELEVIDYS
07:39pm, Friday, 18'th Jul 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today issued the following statement: Shortly after 2:30 p.m. E
'Fast Money' traders on how to play Sarepta after report FDA asked it to stop gene therapy shipments
05:56pm, Friday, 18'th Jul 2025
The 'Fast Money' traders recap the recent news moving Sarepta lower and how to play the stock from here.
LOS ANGELES , July 18, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Sarepta Therapeutics, Inc. ("Sarepta" or "the Company") (NASDAQ: SRPT) for violations
SRPT Investors Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
05:54pm, Friday, 18'th Jul 2025
LOS ANGELES , July 18, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Sarepta Therapeutics, Inc. ("Sarep
NEW YORK, July 18, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed
SRPT Investors Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
03:54pm, Friday, 18'th Jul 2025
LOS ANGELES--(BUSINESS WIRE)---- $SRPT--SRPT Investors Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm.
Sarepta shares fall 37% as FDA questions future of key gene therapy
03:31pm, Friday, 18'th Jul 2025
Shares of Sarepta Therapeutics fell close to 37% on Friday after reports emerged that the US Food and Drug Administration is considering whether to halt the distribution of Elevidys, the company's fla
Sarepta Therapeutics, Inc. investors that lost money are notified to contact BFA Law before the August 25, 2025 securities fraud class action deadline.
Sarepta Therapeutics, Inc. (SRPT) Strategic Restructure and ELEVIDYS Label Update Call Transcript
01:56pm, Friday, 18'th Jul 2025
Sarepta Therapeutics, Inc. (NASDAQ:SRPT ) Strategic Restructure and ELEVIDYS Label Update Conference Call July 16, 2025 4:30 PM ET Company Participants Douglas S. Ingram - President, CEO & Director Ia
Sarepta shares plunge 30% as future of its gene therapy appears at risk
01:13pm, Friday, 18'th Jul 2025
Shares of Sarepta Therapeutics plunged more than 30% on Friday after Food and Drug Administration Commissioner Marty Makary said the agency is considering whether the company's gene therapy should sta
Exclusive: US FDA to request Sarepta to stop all shipments of gene therapy Elevidys, source says
01:11pm, Friday, 18'th Jul 2025
The U.S. Food and Drug Administration will request Sarepta Therapeutics to voluntarily stop all shipments of its gene therapy, Elevidys, a source familiar with the matter told Reuters on Friday.
Sarepta shares sink on 3rd patient death amid restructuring statement
12:04pm, Friday, 18'th Jul 2025
CNBC's Angelica Peebles joins 'Squawk on the Street' with the latest news on Sarepta following a patient death.
Sarepta's Setback Deepens With Another Gene Therapy Fatality
11:43am, Friday, 18'th Jul 2025
Sarepta Therapeutics SRPT shares plummeted on Friday following reports of a third patient death linked to its gene therapy pipeline this year, further clouding investor confidence despite the company'
Sarepta shares sink on third gene therapy-linked death
10:39am, Friday, 18'th Jul 2025
Sarepta Therapeutics Inc (NASDAQ:SRPT) shares pulled back after Thursday's gains on the announcement of a third patient death linked to the company's experimental gene therapies. The patient, who was
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Sarepta Therapeutics, Inc.(SRPT) Shareholders
08:45am, Friday, 18'th Jul 2025
NEW YORK , July 18, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT) of a class action securities lawsuit. CLASS
